Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

Rhea-AI Summary

Myriad Genetics, a leader in genetic testing, will participate in key health and technology conferences in February and March 2021. Executives Paul J. Diaz and R. Bryan Riggsbee will host fireside chats at the BTIG Virtual Conference on February 19, the Leerink Global Healthcare Conference on February 24, and the Cowen Annual Healthcare Conference on March 2. These discussions will focus on enhancing services in Women's Health, Oncology, and Mental Health. Live audio webcasts will be available on Myriad's website.

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Women’s Health, Oncology and Mental Health.

Paul J. Diaz, president and CEO at Myriad Genetics, and R. Bryan Riggsbee, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 19 at 10:30 a.m. EST.

On February 24, 2021, Mr. Riggsbee will participate in a fireside chat at the Leerink Global Healthcare Conference at 5:00 p.m. EST.

On March 2, 2021, Mr. Diaz will participate in a fireside chat at the Cowen Annual Healthcare Conference at 9:50 a.m. EST.

The presentations will be available through a live audio webcast link in the investor information section of Myriad’s website at www.myriad.com.

About Myriad Genetics
Myriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to improving health and transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact:	Jared Maxwell	Investor Contact:	Scott Gleason
	(801) 505-5027		(801) 584-1143
	jmaxwell@myriad.com		sgleason@myriad.com

 

 

 

FAQ

What conferences will Myriad Genetics participate in February 2021?

Myriad Genetics will participate in the BTIG Virtual MedTech Conference on February 19, the Leerink Global Healthcare Conference on February 24, and the Cowen Annual Healthcare Conference on March 2.

Who will represent Myriad Genetics at these conferences?

Paul J. Diaz, the president and CEO, and R. Bryan Riggsbee, the CFO, will represent Myriad Genetics in the upcoming discussions.

What topics will Myriad Genetics discuss at the conferences?

The discussions will emphasize the company's focus on Women's Health, Oncology, and Mental Health.

How can I access the presentations from Myriad Genetics' conferences?

The presentations will be available via live audio webcasts on Myriad's investor information section of their website.

What is the stock symbol for Myriad Genetics?

The stock symbol for Myriad Genetics is MYGN.